Form 144 IRULYA THERAPEUTICS INC For: 21 October
- Investing.com
- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
IRulya Therapeutics Inc (IRLA)
The IRulya share price today is 33.160, view NASDAQ IRLA stock exchange data. Track the latest IRulya share price with real-time updates on IRLA stock performance including market cap, day range, 52-week range and dividend yield. Access IRLA charts, earnings dates and analyst estimates to support your investment decisions.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.850
33.545
52 wk Range
3.660
909.980
Earnings results expected in 15 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
31.85033.545
52 wk Range
3.660909.980
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
IRLA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
75.000
Upside
+126.18%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 75.000
(+126.18% Upside)
Earnings
Latest Release
14-08-2026
EPS / Forecast
-12.31 / -9.40
Revenue / Forecast
-- / --
Compare IRLA to Peers and Sector
Metrics to compare | IRLA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipIRLAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.4x | −1.7x | −0.2x | |
PEG Ratio | 0.00 | −0.01 | 0.00 | |
Price/Book | −0.9x | 1.6x | 2.6x | |
Price / LTM Sales | - | 3.2x | 2.8x | |
Upside (Analyst Target) | 126.2% | 332.6% | 65.5% | |
Fair Value Upside | Unlock | 1.6% | 8.9% | Unlock |
IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene. Its AIDE technology platform is a drug/device combination platform that uses an automated process to encapsulate a drug into a patient’s own red blood cells and consists of automated equipment, the RCL, a sterile single-use consumable treatment kit comprising medical device kits, syringe kits, and process solutions. IRulya Therapeutics Inc. was formerly known as Quince Therapeutics, Inc. and changed its name to IRulya Therapeutics Inc. in October 2026. The company was incorporated in 2012 and is headquartered in New Haven, Connecticut.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the IRulya (IRLA) Share Price Today?
The IRulya share price today is 33.160.
What is the current IRulya (IRLA) share price and day range?
As of 03-11-2026, the IRulya share price is 33.160, with a previous close of 33.550. The share price has ranged from 31.850 to 33.545 today, while the 52-week range spans from 3.660 to 909.980.
What Is the IRulya Market Cap?
As of today, IRulya market cap is 34.120M.
What Is the IRulya (IRLA) Share Price Target?
The average 12-month share price target for IRulya is 75.000, with a high estimate of 98 and a low estimate of 65. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +126.18% Upside potential.
What Is IRulya's Earnings Per Share (TTM)?
The IRulya EPS (TTM) is -51.81.
When Is the Next IRulya Earnings Date?
IRulya will release its next earnings report on 18-11-2026.
From a Technical Analysis Perspective, Is IRLA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
What Stock Exchange Does IRulya Trade On?
IRulya is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for IRulya?
The stock symbol for IRulya is "IRLA."
How Many Times Has IRulya Stock Split?
IRulya has split 2 times.
How Many Employees Does IRulya Have?
IRulya has 38 employees.
What Is the IRLA Premarket Price?
IRLA's last pre-market stock price is 32.800. The pre-market share volume is 60.000, and the stock has changed by -0.750, or -2.240%.
What Is the IRLA After Hours Price?
IRLA's last after hours stock price is 32.090, the stock has changed by -1.070, or -3.230%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.